AstraZeneca Cash on Hand 2010-2023 | AZN

AstraZeneca cash on hand from 2010 to 2023. Cash on hand can be defined as cash deposits at financial institutions that can immediately be withdrawn at any time, and investments maturing in one year or less that are highly liquid and therefore regarded as cash equivalents and reported with or near cash line items.
  • AstraZeneca cash on hand for the quarter ending December 31, 2023 was $6.078B, a 6.38% decline year-over-year.
  • AstraZeneca cash on hand for 2023 was $6.078B, a 6.38% decline from 2022.
  • AstraZeneca cash on hand for 2022 was $6.492B, a 0.17% increase from 2021.
  • AstraZeneca cash on hand for 2021 was $6.481B, a 20.32% decline from 2020.
AstraZeneca Annual Cash on Hand
(Millions of US $)
2023 $6,078
2022 $6,492
2021 $6,481
2020 $8,134
2019 $6,254
2018 $5,938
2017 $4,582
2016 $5,929
2015 $6,855
2014 $7,176
2013 $10,053
2012 $8,555
2011 $11,844
2010 $12,559
2009 $11,402
AstraZeneca Quarterly Cash on Hand
(Millions of US $)
2023-12-31 $6,078
2023-09-30 $5,212
2023-06-30 $5,812
2023-03-31 $6,502
2022-12-31 $6,492
2022-09-30 $5,003
2022-06-30 $4,996
2022-03-31 $5,877
2021-12-31 $6,481
2021-09-30 $7,209
2021-06-30 $15,670
2021-03-31 $7,829
2020-12-31 $8,134
2020-09-30 $8,483
2020-06-30 $6,115
2020-03-31 $4,226
2019-12-31 $6,254
2019-09-30 $4,789
2019-06-30 $6,457
2019-03-31 $5,192
2018-12-31 $5,938
2018-09-30 $4,262
2018-06-30 $3,810
2018-03-31 $3,892
2017-12-31 $4,582
2017-09-30 $5,211
2017-06-30 $6,263
2017-03-31 $3,672
2016-12-31 $5,929
2016-09-30 $4,025
2016-06-30 $4,651
2016-03-31 $4,107
2015-12-31 $6,855
2015-09-30 $4,607
2015-06-30 $4,549
2015-03-31 $3,722
2014-12-31 $7,176
2014-09-30 $5,957
2014-06-30 $5,778
2014-03-31 $5,164
2013-12-31 $10,053
2013-09-30 $8,342
2013-06-30 $9,095
2013-03-31 $8,029
2012-12-31 $8,555
2012-09-30 $6,816
2012-06-30 $9,204
2012-03-31 $10,000
2011-12-31 $11,844
2011-09-30 $10,813
2011-06-30 $10,295
2011-03-31 $10,788
2010-12-31 $12,559
2010-09-30 $11,527
2010-06-30 $11,052
2010-03-31 $9,396
2009-12-31 $11,402
2009-09-30 $7,834
2009-06-30 $7,275
2009-03-31 $4,490
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $219.666B $45.811B
AstraZeneca plc, is one of the largest biopharmaceutical companies in the world. AstraZeneca's business can be broken down into separate lines based on therapeutic classes. These include cardiovascular, respiratory, immunology, oncology, rare diseases and other.In July 2021 AstraZeneca closed the acquisition of rare disease drugmaker, Alexion. The acquisition added Alexion's five marketed rare disease products and its pipeline of immune-mediated rare disease candidates.In order to bolster its respiratory portfolio, AstraZeneca acquired rights to Allergan's branded respiratory business in the U.S. and Canada in Mar 2015. The company also acquired Takeda's core respiratory business in May 2016.In June 2007, AstraZeneca acquired biotechnology company MedImmune. In Aug 2011, AstraZeneca sold its Astra Tech business to DENTSPLY. AstraZeneca entered into a number of deals and struck agreements with companies such as FibroGen and Daiichi Sankyo.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $708.528B 117.99
Novo Nordisk (NVO) Denmark $577.276B 47.56
Johnson & Johnson (JNJ) United States $360.407B 14.30
Merck (MRK) United States $321.391B 84.59
AbbVie (ABBV) United States $300.196B 15.26
Novartis AG (NVS) Switzerland $198.840B 14.10
Pfizer (PFE) United States $149.038B 14.38
Sanofi (SNY) $120.637B 10.86
Innoviva (INVA) United States $0.959B 6.77